Matcha could have little-known side effect that could affect your blood
The polyphenols in matcha, such as catechins and tannins, bind to non-haem iron found in plant-based foods, significantly reducing its absorption in the body.
Vegetarians and vegans are particularly susceptible to this risk as their diets primarily rely on non-haem iron sources like lentils, tofu, and leafy greens.
To mitigate the risk of iron deficiency, it is advised to avoid drinking matcha with meals, especially for those with plant-based diets or who are already iron deficient.
Iron deficiency, also known as anaemia, can lead to symptoms such as tiredness, shortness of breath, and pale skin, and is common among teenage girls, vegans, and vegetarians.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
Americans get more than half their calories from ultraprocessed foods, CDC report says
Most Americans get more than half their calories from ultraprocessed foods, those super-tasty, energy-dense foods typically full of sugar, salt and unhealthy fats, according to a new federal report. Nutrition research has shown for years that ultraprocessed foods make up a big chunk of the U.S. diet, especially for kids and teens. For the first time, however, the U.S. Centers for Disease Control and Prevention has confirmed those high levels of consumption, using dietary data collected from August 2021 to August 2023. The report comes amid growing scrutiny of such foods by Health Secretary Robert F. Kennedy Jr., who blames them for causing chronic disease. 'We are poisoning ourselves and it's coming principally from these ultraprocessed foods,' Kennedy told Fox News earlier this year. Overall, about 55% of total calories consumed by Americans age 1 and older came from ultraprocessed foods during that period, according to the report. For adults, ultraprocessed foods made up about 53% of total calories consumed, but for kids through age 18, it was nearly 62%. The top sources included burgers and sandwiches, sweet baked goods, savory snacks, pizza and sweetened drinks. Young children consumed fewer calories from ultraprocessed foods than older kids, the report found. Adults 60 and older consumed fewer calories from those sources than younger adults. Low-income adults consumed more ultraprocessed foods than those with higher incomes. The results were not surprising, said co-author Anne Williams, a CDC nutrition expert. What was surprising was that consumption of ultraprocessed foods appeared to dip slightly over the past decade. Among adults, total calories from those sources fell from about 56% in 2013-2014 and from nearly 66% for kids in 2017-2018. Williams said she couldn't speculate about the reason for the decline or whether consumption of less processed foods increased. But Andrea Deierlein, a nutrition expert at New York University who was not involved in the research, suggested that there may be greater awareness of the potential harms of ultraprocessed foods. ' People are trying, at least in some populations, to decrease their intakes of these foods,' she said. Concern over ultraprocessed foods' health effects has been growing for years, but finding solutions has been difficult. Many studies have linked them to obesity, diabetes and heart disease, but they haven't been able to prove that the foods directly cause those chronic health problems. One small but influential study found that even when diets were matched for calories, sugar, fat, fiber and micronutrients, people consumed more calories and gained more weight when they ate ultraprocessed foods than when they ate minimally processed foods. Research published this week in the journal Nature found that participants in a clinical trial lost twice as much weight when they ate minimally processed foods — such as pasta, chicken, fruits and vegetables — than ultraprocessed foods, even those matched for nutrition components and considered healthy, such as ready-to-heat frozen meals, protein bars and shakes. Part of the problem is simply defining ultraprocessed foods. The new CDC report used the most common definition based on the four-tier Nova system developed by Brazilian researchers that classifies foods according to the amount of processing they undergo. Such foods tend to be 'hyperpalatable, energy-dense, low in dietary fiber and contain little or no whole foods, while having high amounts of salt, sweeteners and unhealthy fats,' the CDC report said. U.S. health officials recently said there are concerns over whether current definitions 'accurately capture' the range of foods that may affect health. The U.S. Food and Drug Administration and the Agriculture Department recently issued a request for information to develop a new, uniform definition of ultraprocessed foods for products in the U.S. food supply. In the meantime, Americans should try to reduce ultraprocessed foods in their daily diets, Deierlein said. For instance, instead of instant oatmeal that may contain added sugar, sodium, artificial colors and preservatives, use plain oats sweetened with honey or maple syrup. Read food packages and nutrition information, she suggested. 'I do think that there are less-processed options available for many foods,' she said. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Daily Mail
4 hours ago
- Daily Mail
Pill that costs just pennies a day linked to decreased risk of dementia, study suggests
Doctors are zeroing in on ways to prevent dementia, and the secret weapon could be an inexpensive drug that has served as the backbone for diabetes treatment for decades. Long before Ozempic splashed onto the scene, transforming type 2 diabetes treatment, there was metformin. Used for about 100 years, metformin lowers the amount of sugar the liver pumps out and helps the body respond to insulin better. It has been the first-line treatment for more than 70 percent of people newly diagnosed with type 2 diabetes. Doctors have suggested through observational studies for several years that the mainstay of diabetes, which roughly 19 million people take for $2 to $20 per month, could have preventive power. Still, evidence has been mixed, with some studies suggesting the drug exacerbates the development of Alzheimer's disease, just one type of dementia, and several others saying it has a protective effect on the brain. Now, doctors from Taipei Medical University in Taiwan are the latest to make the case for the latter. They found that, in half a million overweight and obese people without diabetes, those who took metformin had a lower risk of developing dementia or dying from any cause, regardless of their BMI. Similar to type 2 diabetes, obesity is a risk factor for dementia. Being severely overweight lowers the body's defenses against the damage dementia inflicts on the brain and causes chronic inflammation, potentially damaging nerve cells. Until now, research into metformin as a dementia preventative has primarily focused on people with diabetes. The latest report from Taiwanese researchers is the first to use real-world data to investigate the possibility in people with obesity. The scientists noted the real-world data reflects a diverse population, making the study's findings widely applicable. They used an electronic health records database covering millions of patients from 66 US healthcare systems, including hospitals, specialty centers, and clinics. The researchers said: 'Since central nervous system inflammation and neuroinflammation are crucial factors in the development and progression of neurodegenerative diseases, the anti-inflammatory and antioxidative effects of metformin are especially beneficial in patients with obesity. 'Regular, long-term use of metformin may be an efficient way to prevent dementia.' The study included about 905,000 people in total, split evenly into two groups: those on and those not on metformin. They were matched to be similar in age, health, and other factors for a fair comparison. The metformin group had been prescribed the drug at least twice in their lives for at least six months. The study did not explicitly state why people had been prescribed the drug, but it can be used to treat more than just diabetes, such as prediabetes, those with a metabolic disorder that contributes to obesity, and for polycystic ovary syndrome. Researchers categorized their study subjects, all adults over 18, into four groups: overweight (BMI 25–29.9), Obese class I (BMI 30–34.9), Obese class II (BMI 35–39.9) and morbidly obese (BMI over 40). After following patients for 10 years, those who took metformin had a lower risk of developing dementia across all BMI groups. The amount of risk reduction varied slightly depending on weight, but two of the groups saw significant results. People with a BMI of 30 to 34.9 had a dementia risk about eight percent lower than non-users, while those with a BMI between 25 and 29.9 had a risk about 12.5 percent lower. People with a BMI of 35 to 39.9 had a four percent lower risk, which researchers deemed statistically insignificant, potentially due to a smaller sample size. There was no significant difference in people with a BMI over 40. When looking at death from any cause, metformin users also had a significantly lower risk across all BMI categories. Metformin's effect on death risk was stronger than its effect on dementia risk. Those with a BMI between 25 and 29.9 had a 28 percent lower risk of death, while those with a BMI of 30 to 34.9 had a 27 percent lower risk. People with a BMI of 35 to 39.9 had a 28 percent lower risk of death, and people with a BMI of 40 or above saw a 26 percent lower risk. The Taipei team's findings were published in the journal Diabetes, Obesity and Metabolism. Scientists attribute metformin's recently explored impact on cognitive health and dementia to factors unique to the drug and the condition it treats. A type 2 diabetes diagnosis is a leading risk factor for dementia, with one sweeping review in 2013 finding that diabetes patients have a 73 percent higher likelihood of developing dementia and a 56 percent higher likelihood of developing Alzheimer's. Both conditions affect millions in the US. Around 35 million Americans have type 2 diabetes, while an estimated 7million have dementia, including roughly four to 6 million with Alzheimer's disease. Several studies have resulted in compelling evidence that supports metformin's anti-dementia abilities. In 2020, Australian researchers followed over 1,000 dementia-free seniors aged 70 to 90 from Sydney for up to six years, testing their memory and thinking skills at two and six years. The study looked at three main groups: people with type 2 diabetes who were taking metformin, those with diabetes who were not, and people without diabetes. The participants in the study, who did not have dementia at the start, were tested at two years and again at six years for their in-depth memory and executive functioning. After accounting for other health factors, researchers found that the metformin group had an 81 percent lower risk of dementia compared to those with diabetes who weren't on metformin. People with diabetes who didn't take metformin were nearly three times more likely to develop dementia than people without diabetes. Brain scans and thinking tests also suggested that metformin users experienced a slower decline in cognitive abilities, particularly in decision-making and overall brain function.
The Independent
5 hours ago
- The Independent
What is the ‘herb of grace' and how does it benefit your health?
Bacopa Monnieri, also known as brahmi or the 'herb of grace,' has been utilized for centuries in Indian Ayurveda traditional medicine. It is believed to offer brain -boosting benefits, primarily through its antioxidant properties that help protect the brain by stimulating the body's natural defense system. The herb functions as an adaptogen, potentially reducing stress by interacting with the hypothalamic-pituitary-adrenal axis, which regulates the body's stress response. Studies indicate that Bacopa Monnieri can reduce inflammation in the central nervous system and alleviate related pain, with chronic inflammation being linked to various health issues. While generally considered safe, not all risks have been thoroughly studied; it is advisable to consult a doctor and opt for supplements verified by a third party.
